CDK 4/6 Inhibition in Breast Cancer: Self-Study Module I

CDK 4/6 Inhibition in Breast Cancer: Self-Study Module I is organized by RealCME.

Primary Audience:
Oncology nurses, nurse navigators, nurse practitioners, physician assistants, medical technicians, and other healthcare professionals involved in the care and management of patients with advanced or metastatic breast cancer.

Credits:
1 ANCC Contact Hours 1 AMA PRA Category 1 Credit(s)™

Learning Objectives:
• Discuss the risks and benefits of CDK 4/6 inhibitors for the treatment of estrogen receptor–positive, HER2-negative advanced breast cancer with patients and their families
• Describe education/shared decision-making strategies to help patients understand their treatment options in estrogen receptor–positive, HER2-negative advanced breast cancer
• Evaluate proper dosing administration, monitoring, and adherence strategies of CDK 4/6 inhibitors for the treatment of estrogen receptor–positive, HER2-negative advanced breast cancer
• Describe the role of a nurse navigator in the management of patients with advanced or metastatic breast cancer being treated with CDK 4/6 inhibitors

Additional details will be posted as soon as they are available.